Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Claro Advisors LLC

Claro Advisors LLC lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 34.9% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,799 shares of the biopharmaceutical company’s stock after selling 2,569 shares during the period. Claro Advisors LLC’s holdings in Gilead Sciences were worth $402,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. nVerses Capital LLC acquired a new position in shares of Gilead Sciences in the 3rd quarter valued at about $25,000. CarsonAllaria Wealth Management Ltd. boosted its stake in Gilead Sciences by 198.3% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 238 shares during the period. Palisade Asset Management LLC acquired a new position in Gilead Sciences in the first quarter valued at approximately $29,000. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Gilead Sciences during the 2nd quarter worth approximately $33,000. Finally, Cedar Wealth Management LLC lifted its holdings in shares of Gilead Sciences by 51.6% in the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 160 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on GILD. Royal Bank of Canada increased their target price on Gilead Sciences from $74.00 to $75.00 and gave the stock a “sector perform” rating in a research report on Friday, October 4th. JPMorgan Chase & Co. increased their price objective on shares of Gilead Sciences from $95.00 to $100.00 and gave the stock an “overweight” rating in a report on Wednesday, October 9th. Raymond James raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 target price for the company in a research note on Monday, July 8th. Sanford C. Bernstein started coverage on shares of Gilead Sciences in a research note on Thursday. They issued an “outperform” rating and a $105.00 price target on the stock. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $70.00 price target on shares of Gilead Sciences in a report on Monday, September 16th. Ten analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $86.37.

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the sale, the insider now owns 78,127 shares in the company, valued at approximately $6,545,480.06. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the sale, the insider now owns 78,127 shares in the company, valued at approximately $6,545,480.06. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the sale, the insider now owns 100,189 shares in the company, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 36,847 shares of company stock worth $3,033,340. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $86.72 on Friday. The business’s 50-day moving average price is $81.06 and its 200 day moving average price is $72.81. The firm has a market cap of $108.04 billion, a P/E ratio of 240.89, a PEG ratio of 2.98 and a beta of 0.18. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $87.86. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.61 by $0.40. The firm had revenue of $6.95 billion for the quarter, compared to analyst estimates of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 3.78 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 27th. Shareholders of record on Friday, September 13th were issued a dividend of $0.77 per share. The ex-dividend date was Friday, September 13th. This represents a $3.08 annualized dividend and a yield of 3.55%. Gilead Sciences’s payout ratio is presently 855.56%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.